PLX R18

Drug Profile

PLX R18

Alternative Names: PLX R 18; PLX RAD

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Hadassah Medical School; Pluristem Therapeutics
  • Developer Case Western Reserve University; Hadassah Medical School; National Institute of Allergy and Infectious Diseases; Pluristem Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Bone marrow cell stimulants; Cell differentiation modulators; Cell replacements; Granulocyte colony stimulating factor stimulants; Interleukin-6 modulators; Stem cell modulators; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aplastic anaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Aplastic anaemia; Graft-versus-host disease
  • Preclinical Acute radiation syndrome

Most Recent Events

  • 08 Feb 2017 Phase-I clinical trials in Graft-versus-host disease in USA (IM) (NCT03002519)
  • 07 Nov 2016 Pluristem Therapeutics receives patent allowance for adherent cells from adipose or placental tissues and their therapeutics use in China
  • 13 May 2016 Pluristem announces intention to submit BLA to US FDA under the Animal Rule regulatory pathway for Acute radiation syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top